Resources
News & Events
Coming soon: European patient survey on CAR T-cell therapy – Help us to gain insights into patients’ experiences, quality of life and unmet needs
After months of preparation and close collaboration with patient advocacy groups, patients and carers, we are proud to launch our European patient survey on CAR T-cell therapy! This survey will help us to understand patients’ experiences with CAR T-cell therapy,...
EHA2022 Congress
The EHA congress in Vienna is getting closer! https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/ If you are joining the event please be sure to stop by the T2EVOLVE walk-in room on Saturday 11th June 10:30am-12:30pm (Room Schubert 2) where we can meet and...
Bioprocessing Pharma 4.0 | May 11th-13th ,Frankfurt, Germany
Helene Negre presenting T2EVOLVE.
ICLE 2022 |31th March – 2st April Munich
Maik Luu will present T2EVOLVE at the ICLE in Munich (31th March- 2nd April).
DIA EUROPE 2022 | 29-31 MARCH 2022 BRUSSELS &VIRTUAL
Helene Negre has been invited to speak during the upcoming DIA Europe 2022 on March 31 in Brussels.
SFTCG Annual Meeting | 16-18 March 2022
Helene Negre will present T2EVOLVE at annual meeting SFTCG on Thursday 17th March at 11:30 am
Latest Tweets
Publications
- Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
- Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
- CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models
- Targeting metabolic rewiring might decrease spread of tumor cells: Mitochondrial tRNA modifications promote cancer metastasis
- CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
- CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome
Materials
